Abbott Laboratories (NYSE:ABT) Price Target Raised to $123.00

25 Oct 2026, 05:42 by Sarita Garza · The Markets Daily

Abbott Laboratories (NYSE:ABT – Free Report) had its price target increased by Robert W. Baird from $121.00 to $123.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an outperform rating on the healthcare product maker’s stock.

A number of other brokerages also recently commented on ABT. Barclays assumed coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. BTIG Research raised their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, UBS Group lowered their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.32.

View Our Latest Report on Abbott Laboratories

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $103.70 on Thursday. The firm has a 50-day simple moving average of $105.15 and a 200-day simple moving average of $98.32. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $179.45 billion, a price-to-earnings ratio of 38.70, a price-to-earnings-growth ratio of 1.92 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The firm had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. During the same period in the previous year, the business posted $1.30 earnings per share. Abbott Laboratories’s quarterly revenue was up 14.5% on a year-over-year basis. On average, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is currently 94.03%.

Institutional Trading of Abbott Laboratories

Institutional investors and hedge funds have recently bought and sold shares of the stock. IVC Wealth Advisors LLC acquired a new position in Abbott Laboratories in the third quarter valued at about $241,000. Holos Integrated Wealth LLC lifted its holdings in shares of Abbott Laboratories by 40.3% in the 3rd quarter. Holos Integrated Wealth LLC now owns 888 shares of the healthcare product maker’s stock worth $92,000 after acquiring an additional 255 shares during the last quarter. Kingswood Wealth Advisors LLC lifted its holdings in shares of Abbott Laboratories by 7.3% in the 3rd quarter. Kingswood Wealth Advisors LLC now owns 12,712 shares of the healthcare product maker’s stock worth $1,257,000 after acquiring an additional 863 shares during the last quarter. Financial Management Professionals Inc. boosted its position in shares of Abbott Laboratories by 2.1% during the 3rd quarter. Financial Management Professionals Inc. now owns 5,878 shares of the healthcare product maker’s stock worth $581,000 after purchasing an additional 119 shares during the period. Finally, Compass Ion Advisors LLC boosted its position in shares of Abbott Laboratories by 7.0% during the 3rd quarter. Compass Ion Advisors LLC now owns 5,106 shares of the healthcare product maker’s stock worth $505,000 after purchasing an additional 332 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.